The Drug Eluting Stents Center

Filter Your Results




Financing Will Support Orchestra BioMed's Product Pipeline Development

July 10, 2019 -- Orchestra BioMed, Inc. announced that financing will be used to accelerate and expand development of the company's lead and pipeline assets, including Bac…

FDA Paclitaxel Advisory Meeting Day 1: Panel Addresses Updated Data, Signal Presence, Class Effect, Missing Data, Subgroups, and Causes of Death

June 19, 2019 -- Among efforts to explore and address concerns raised by recent meta-analysis data that found an increased mortality signal in patients treated with lower extr…

FDA Advisory Meeting Day 2: Panel Weighs the Future of Paclitaxel and Clinical Trials in PAD

June 20, 2019 -- After a full first day of presentations, questions, deliberations, and recommendations, US FDA advisors reconvened to address additional queries posed by the …

JEVT Editorial Challenges Drug Dosing and Exposure Time Assumptions in Paclitaxel Mortality Meta-Analysis

June 17, 2019 -- A recent editorial in the Journal of Endovascular Therapy (JEVT) challenges several key assumptions and findings of the recent meta-analysis by Konstantinos K…

Orchestra BioMed Partners With Terumo to Develop and Commercialize the Virtue Sirolimus-Eluting Balloon

June 13, 2019 -- Orchestra BioMed, Inc. announced it has formed a global strategic partnership with Terumo Corporation for development and commercialization of Virtue sirolimu…

UK MHRA Issues Recommendations on Use of Paclitaxel Devices in PAD

June 6, 2019 -- The United Kingdom Medicines & Healthcare Products Regulatory Agency (UK MHRA) announced that it has issued the agency's recommendations for ongoing us…

Editorial Articles in JAHA Address Paclitaxel in PAD Studies

May 31, 2019 -- A series of editorial articles and letters published online in Journal of the American Heart Association (JAHA) continue to evaluate the data and discuss the c…

SWEDEPAD Trials Explore Resumption of Enrollment

May 31, 2019 -- Investigators from the SWEDEPAD 1 and 2 trials are aiming to resume recruitment of patients, having reviewed mortality data from the trials following conc…




Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.